Trial Profile
Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Lomustine (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- Acronyms CeTeG; CeTeG/NOA-09
- 01 Jan 2023 Results assessing high grade hematotoxicity and its prognostic relevance, published in the Journal of Neuro-Oncology.
- 02 Sep 2019 Results assessing health-related quality of life and neurocognitive function published in the Lancet Oncology.
- 31 May 2017 Status changed from active, no longer recruiting to completed.